Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 598 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EconoPred Plus Clear all
Terminated Phase 4 Interventional Results available

Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures

NCT03898154
View directory record Official record
Conditions
Distal Radius Fracture
Interventions
Dexamethasone, Methylprednisolone
Drug
Lead sponsor
C. Liam Dwyer
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 3 Interventional

Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia

NCT00015873
View directory record Official record
Conditions
Leukemia
Interventions
asparaginase, cytarabine, mercaptopurine, methotrexate, prednisolone, vincristine sulfate
Drug
Lead sponsor
Dutch Childhood Oncology Group
Other
Eligibility
Up to 1 Year
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Not applicable Interventional

A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

NCT03324503
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Glucocorticoid (prednisone or prednisolone)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Birmingham, Alabama • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 25, 2026, 2:58 PM EDT
Terminated Not applicable Interventional

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

NCT00006054
View directory record Official record
Conditions
Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Hyper IgM Syndrome, Severe Combined Immunodeficiency, Leukocyte Adhesion Deficiency Syndrome, Virus-Associated Hemophagocytic Syndrome
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, methylprednisolone, prednisone, Allogeneic Bone Marrow Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
Up to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Increases After Shoulder Injection

NCT05438277
View directory record Official record
Conditions
Shoulder Pain
Interventions
Methylprednisolone (MPA), Triamcinolone Acetonide (TA)
Drug
Lead sponsor
Campbell Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
421 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Results available

Lumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial)

NCT01238536
View directory record Official record
Conditions
Spinal Stenosis, Low Back Pain
Interventions
Epidural steroid with local anesthetic injection, Epidural local anesthetic injection, Epidural steroid injection, Epidural local anesthetic injection
Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Redwood City, California • Roseville, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 3 Interventional

Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease

NCT00053976
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Daclizumab, methylprednisolone, Placebo
Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
8
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma

NCT01691508
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, OCS (prednisone/prednisolone)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Long Beach, California • Denver, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

NCT02953678
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Prednisone or methylprednisolone
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients

NCT00240994
View directory record Official record
Conditions
Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions
Alemtuzumab, Tacrolimus, Mycophenolate mofetil, Sirolimus
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 25, 2026, 2:58 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Autologous Transplant To End NMO Spectrum Disorder

NCT03829566
View directory record Official record
Conditions
Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
Interventions
Rituximab, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 25, 2026, 2:58 PM EDT
Not yet recruiting Phase 4 Interventional

OMT for Adhesive Capsulitis

NCT07497737
View directory record Official record
Conditions
Adhesive Capsulitis of the Shoulder, Frozen Shoulder
Interventions
Intra-articular Injection, Osteopathic Manipulative Therapy (OMT)
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Beachwood, Ohio • Westlake, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Not listed Phase 2 Interventional

Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse

NCT00069966
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, cisplatin, cytarabine, methylprednisolone, pixantrone dimaleate, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
28
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2009 · Synced Oct 25, 2026, 2:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pharmacokinetic Interactions With Prednisolone in Healthy Volunteers and HIV-infected Patients Receiving Single-Dose Prednisone

NCT00072644
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Results available

ED-Initiated School-based Asthma Medication Supervision

NCT03952286
View directory record Official record
Conditions
Asthma, Asthma in Children
Interventions
ED-Dispensing home and school supervision
Drug
Lead sponsor
University of Arizona
Other
Eligibility
6 Years to 12 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 25, 2026, 2:58 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Golcadomide, Rituximab, Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone, Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
31
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 25 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

NCT03113695
View directory record Official record
Conditions
Richter's Syndrome, CLL
Interventions
Obinutuzumab, lenalidomide, HDMP
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 25, 2026, 2:58 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

TAP Block Using Liposomal Bupivacaine for Post-cesarean Delivery Analgesia- Walking Towards Recovery

NCT04393207
View directory record Official record
Conditions
Opioid Use, Pain, Acute
Interventions
Liposomal bupivacaine (LB), Dexamethasone and methylprednisolone (CG), Control group (Bupivacaine)- (BPG)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00004904
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 25, 2026, 2:58 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

NCT03920007
View directory record Official record
Conditions
Leber Congenital Amaurosis, LCA, LCA1
Interventions
ATSN-101, ATSN-101 Diluent Solution, Prednisone, Triamcinalone Acetonide, 1% Prednisolone, Trimethoprim/polymyxin B
Drug
Lead sponsor
Atsena Therapeutics Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

NCT00066417
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
Interventions
cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, therapeutic allogeneic lymphocytes, thiotepa, allogeneic bone marrow transplantation, biological therapy, bone marrow ablation with stem cell support, bone marrow transplantation, chemotherapy, leukocyte therapy, non-specific immune-modulator therapy, peripheral blood lymphocyte therapy, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Inborn Errors of Metabolism

NCT00176904
View directory record Official record
Conditions
Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Gaucher's Disease, Fucosidosis, Wolman Disease, Niemann-Pick Disease, Batten Disease, GM1 Gangliosidosis, Tay Sachs Disease, Sandhoff Disease
Interventions
Stem Cell Transplant, Busulfan, Cyclophosphamide, Antithymocyte Globulin
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 25, 2026, 2:58 PM EDT
Terminated Not applicable Interventional Results available

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

NCT00608517
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, methylprednisolone, total-body irradiation
Biological · Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Up to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Results available

Dropless vs. Standard Drops Contralateral Eye Study

NCT02515045
View directory record Official record
Conditions
Cataract
Interventions
TriMoxiVanc, Moxifloxacin HCl 0.5%, Ilevro, Prednisolone acetate 1%
Drug
Lead sponsor
Carolina Eyecare Physicians, LLC
Other
Eligibility
50 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Bloomington, Minnesota • Stillwater, Minnesota • Garden City, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 25, 2026, 2:58 PM EDT